• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings

    4/4/24 11:58:56 AM ET
    $ACHL
    $ALUR
    $CADL
    $CAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ACHL alert in real time by email

    U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday.

    The Dow traded up 0.49% to 39,319.03 while the NASDAQ rose 1% to 16,4340. The S&P 500 also rose, gaining, 0.75% to 5,250.72.

    Check This Out: Insiders Buying Walgreens And 2 Other Stocks

     

    Leading and Lagging Sectors

     

    Real estate shares jumped by 1.1% on Thursday.

    In trading on Thursday, health care shares rose by just 0.01%.

     

    Top Headline

     

    ConAgra Brands Inc (NYSE:CAG) reported better-than-expected third-quarter financial results.

    ConAgra reported a third-quarter FY24 sales decline of 1.7% year-on-year to $3.03 billion, beating the analyst consensus estimate of $3.01 billion. Adjusted EPS of 69 cents beat the consensus estimate of 65 cents.

    ConAgra reaffirmed its outlook for FY24 Organic net sales to decrease between 1.0% and 2.0% compared to fiscal 2023.

     

    Equities Trading UP

     

    TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares shot up 76% to $2.2850. TCBP announced execution of non-binding letter of intent for acquisition of NK Platform Technologies.

    Shares of Allurion Technologies Inc. (NASDAQ:ALUR) got a boost, surging 116% to $3.73 after the company announced the commercial availability of its Virtual Care Suite in the United States. Also, Chardan Capital initiated coverage on the stock with a Buy rating and announced a $5 price target.

    Candel Therapeutics, Inc. (NASDAQ:CADL) shares were also up, gaining 39% to $2.3383 after the company announced interim data from the randomized phase 2 clinical trial of CAN-2409 in non-metastatic prostate cancer.

     

    Equities Trading DOWN

     

    eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) shares dropped 76% to $3.9778. The company announced topline results from the primary analysis of the randomized Phase 2 KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer.

    Shares of Achilles Therapeutics plc (NASDAQ:ACHL) were down 27% to $0.8706 after the company reported fourth-quarter financial results. The company announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer and the THETIS study in recurrent or metastatic malignant melanoma.

    KWESST Micro Systems Inc. (NASDAQ:KWE) was down, falling 17% to $0.9385 after the company announced a proposed US public offering.

    Also Check This Out: Top 3 Real Estate Stocks That Are Ticking Portfolio Bombs

     

    Commodities

     

    In commodity news, oil traded down 0.2% to $85.27 while gold traded up 0.4% at $ 2,317.30.

    Silver traded up 0.5% to $27.185 on Thursday, while copper rose 1% to $4.2365.

     

    Euro zone

     

    European shares were mostly higher today. The eurozone’s STOXX 600 rose 0.22%, London’s FTSE 100 rose 0.49% while Spain’s IBEX 35 Index rose 0.52% The German DAX rose 0.23% French CAC 40 rose 0.07% while Italy’s FTSE MIB Index rose 0.01%.

    Industrial producer prices in the eurozone fell by 1.0% from the prior month in February compared to a 0.9% decline in the prior month, while services PMI climbed to 51.5 in March versus 50.2 in the earlier month.

    The HCOB France services PMI fell to 48.3 in March versus 48.4 a month ago, while German services PMI rose to 50.1 in March versus a preliminary reading of 49.8. The S&P Global UK services PMI fell to 53.1 in March versus 53.8 in the prior month.

     

    Asia Pacific Markets

     

    Asian markets closed higher on Thursday, with Japan’s Nikkei 225 gaining 0.81% and India’s S&P BSE Sensex rising 0.5%.

    The HSBC Indian services PMI rose to 61.2 in March versus a preliminary reading of 60.3 and compared to a final reading of 60.6 in the prior month.

     

    Economics

     

    U.S. jobless claims rose by 11,000 from the previous week’s revised reading to 221,000 on March, the most in two months.

    U.S. trade deficit increased to $68.9 billion in February versus a revised $67.6 billion gap in the previous month.

    Now Read This: Levi Strauss, Conagra Brands And 3 Stocks To Watch Heading Into Thursday

    Get the next $ACHL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHL
    $ALUR
    $CADL
    $CAG

    CompanyDatePrice TargetRatingAnalyst
    Candel Therapeutics Inc.
    $CADL
    10/28/2025$15.00Overweight
    Stephens
    Candel Therapeutics Inc.
    $CADL
    9/3/2025$7.00Buy → Neutral
    BofA Securities
    ConAgra Brands Inc.
    $CAG
    8/20/2025$20.00Neutral
    Analyst
    Candel Therapeutics Inc.
    $CADL
    6/30/2025$23.00Buy
    H.C. Wainwright
    ConAgra Brands Inc.
    $CAG
    6/16/2025$22.00Neutral
    UBS
    ConAgra Brands Inc.
    $CAG
    6/12/2025$20.00Neutral → Underperform
    BofA Securities
    ConAgra Brands Inc.
    $CAG
    6/9/2025$21.00Neutral → Sell
    Goldman
    ConAgra Brands Inc.
    $CAG
    3/24/2025$27.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ACHL
    $ALUR
    $CADL
    $CAG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Brown Thomas K bought $187,200 worth of shares (10,000 units at $18.72), increasing direct ownership by 20% to 60,167 units (SEC Form 4)

    4 - CONAGRA BRANDS INC. (0000023217) (Issuer)

    10/9/25 4:45:52 PM ET
    $CAG
    Packaged Foods
    Consumer Staples

    Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    5/21/25 4:15:08 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    4/1/25 4:15:07 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ACHL
    $ALUR
    $CADL
    $CAG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

    NEEDHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Francesca Barone, M.D., Ph.D., Candel's Chief Scientific Officer, will present data and participate in multiple sessions at the 7th Annual Glioblastoma Drug Development Summit, taking place February 17-19, 2026 in Boston, Massachusetts. Dr. Barone will share insights from Candel's HSV-based platform and the linoserpaturev (CAN-3110) program in recurrent high-grade glioma (rHGG) through workshop presentations and panel discu

    2/11/26 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices

    Through Bionut, a leader in obesity care in Argentina, Allurion Program patients will now have access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced a partnership with Bionut, a leader in obesity care in Argentina, and Farmastar, a local pharmacy partner with access to the official supplier of Mounjaro (tirzepatide) in Argentina, to provide patients with access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule. "The obesity epidemic is growing, and patients are in need of more therapeutic options," said Romina Sapir, Di

    2/3/26 9:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    CONAGRA BRANDS ANNOUNCES DETAILS OF 2026 CAGNY CONFERENCE PRESENTATION WEBCAST

    CHICAGO, Feb. 3, 2026 /PRNewswire/ -- Conagra Brands, Inc. (NYSE:CAG) will present at the 2026 CAGNY (Consumer Analyst Group of New York) Conference on Tuesday, Feb. 17, at 9 a.m. ET.   Sean Connolly, president and chief executive officer of Conagra Brands, Dave Marberger, executive vice president and chief financial officer, and Bob Nolan, senior vice president of growth science, will present information on Conagra Brands' business strategies and financial outlook.   A video webcast of the presentation and presentation slides will be available on conagrabrands.com/investor-re

    2/3/26 7:30:00 AM ET
    $CAG
    Packaged Foods
    Consumer Staples

    $ACHL
    $ALUR
    $CADL
    $CAG
    SEC Filings

    View All

    SEC Form EFFECT filed by Allurion Technologies Inc.

    EFFECT - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    1/20/26 12:15:36 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    1/12/26 4:30:27 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    SEC Form S-3 filed by Allurion Technologies Inc.

    S-3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    1/9/26 5:24:35 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ACHL
    $ALUR
    $CADL
    $CAG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Technology Officer Tyagarajan Seshu

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    1/28/26 5:04:50 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Medical Officer Nichols William Garrett

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    1/28/26 5:03:33 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Financial Officer Schoch Charles

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    1/28/26 5:02:42 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    $ALUR
    $CADL
    $CAG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens initiated coverage on Candel Therapeutics with a new price target

    Stephens initiated coverage of Candel Therapeutics with a rating of Overweight and set a new price target of $15.00

    10/28/25 8:02:46 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Candel Therapeutics from Buy to Neutral and set a new price target of $7.00

    9/3/25 8:04:26 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Analyst resumed coverage on Conagra with a new price target

    Analyst resumed coverage of Conagra with a rating of Neutral and set a new price target of $20.00

    8/20/25 8:33:34 AM ET
    $CAG
    Packaged Foods
    Consumer Staples

    $ACHL
    $ALUR
    $CADL
    $CAG
    Leadership Updates

    Live Leadership Updates

    View All

    Valmont Appoints William Eric Johnson as Chief Accounting Officer

    Valmont® Industries, Inc. (NYSE:VMI), a global leader that provides products and solutions to support vital infrastructure and advance agricultural productivity, today announced William "Eric" Johnson will join the company as Chief Accounting Officer effective October 20, 2025. Mr. Johnson will be an integral leader on the finance team overseeing the Company's accounting and SEC reporting functions, and reporting directly to Tom Liguori, Executive Vice President and Chief Financial Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020792689/en/William "Eric" Johnson Prior to joining Valmont, Mr. Johnson served as Senior

    10/20/25 8:00:00 AM ET
    $CAG
    $VMI
    Packaged Foods
    Consumer Staples
    Metal Fabrications
    Industrials

    Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

    NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Bali Pulendran, Ph.D. to Candel's Research Advisory Board (RAB). Dr. Pulendran, an internationally recognized expert in systems immunology and vaccinology, who has pioneered the use of systems approaches to understand human immune responses, will bring his deep expertise to the RAB, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-311

    10/16/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

    NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Carl H. June, M.D., to Candel's Research Advisory Board (RAB). Dr. June, an internationally recognized expert in cancer immunotherapy, and a pioneer in developing the first U.S. Food and Drug Administration (FDA)-approved CAR-T cell therapy, will bring Candel his deep expertise, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-3110 f

    9/2/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    $ALUR
    $CADL
    $CAG
    Financials

    Live finance-specific insights

    View All

    CONAGRA BRANDS REPORTS SECOND QUARTER RESULTS

    CHICAGO, Dec. 19, 2025 /PRNewswire/ -- Today Conagra Brands, Inc. (NYSE:CAG) reported results for the second quarter of fiscal year 2026, which ended on November 23, 2025. All comparisons are against the prior year fiscal period, unless otherwise noted. Highlights Reported net sales decreased 6.8%; organic net sales decreased 3.0%.Reported operating margin was (20.1)%; adjusted operating margin was 11.3%.Reported diluted loss per share was $1.39, primarily as a result of certain non-cash goodwill and brand impairment charges, and adjusted earnings per share (EPS) were $0.45.Th

    12/19/25 7:30:00 AM ET
    $CAG
    Packaged Foods
    Consumer Staples

    Conagra Brands Announces Quarterly Dividend Payment

    CHICAGO, Dec. 18, 2025 /PRNewswire/ -- Conagra Brands, Inc. (NYSE:CAG) today announced that its Board of Directors approved a quarterly dividend payment of $0.35 per share of CAG common stock to be paid on February 26, 2026 to stockholders of record as of the close of business on January 27, 2026. Conagra Brands, Inc. has paid consecutive quarterly dividends since January 1976. About Conagra BrandsConagra Brands, Inc. (NYSE:CAG), is one of North America's leading branded food companies. We combine a 100-year history of making quality food with agility and a relentless focus on

    12/18/25 7:30:00 AM ET
    $CAG
    Packaged Foods
    Consumer Staples

    Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update

    Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the third quarter and provided a business update. Recent Company Highlights Successfully passed U.S. Food and Drug Administration ("FDA") Pre-Approval Inspection and Bioresearch Monitoring (BIMO) audit with zero observations and no Form 483 issued Completed Premarket Approval ("PMA") Acceptance and Filing Reviews, entered Substantive Review for the Allurion Smart Capsule and successfully completed Day-100 meeting Entered into transaction to exchange all outstanding debt for convertible preferred equity and concurrently announced private placement fina

    11/12/25 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ACHL
    $ALUR
    $CADL
    $CAG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by KWESST Micro Systems Inc.

    SC 13G - KWESST Micro Systems Inc. (0001889823) (Subject)

    11/14/24 5:34:02 PM ET
    $KWE
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

    SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    11/14/24 4:43:43 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care